Tandem Diabetes Care TNDM Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tandem Diabetes Care's unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tandem Diabetes Care's unrealized gains (losses) on available-for-sale securities?
- Tandem Diabetes Care (TNDM) reported unrealized gains (losses) on available-for-sale securities of -$1.03M in Q1 2026.
- How has Tandem Diabetes Care's unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Tandem Diabetes Care's unrealized gains (losses) on available-for-sale securities decreased by 342.8% year-over-year, from $423K to -$1.03M.
- What is the long-term trend for Tandem Diabetes Care's unrealized gains (losses) on available-for-sale securities?
- Over 2 years (2023 to 2025), Tandem Diabetes Care's unrealized gains (losses) on available-for-sale securities has grown at a -60.4% compound annual growth rate (CAGR), from $3.61M to $566K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This reflects the change in the fair value of investment securities that are classified as available-for-sale but have not yet been sold. It captures unrealized gains or losses that bypass the income statement and are instead recorded directly in equity. This metric helps investors understand the volatility and market-driven fluctuations in the company's investment portfolio.